Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 17;5(4):366-375.
doi: 10.1002/osp4.342. eCollection 2019 Aug.

Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study

Y L Zhang  1 , C Zhou  2 , X F Li  1 , M N Yang  1 , L Tao  2 , X Y Zheng  2 , Y S Jia  3
Affiliations

Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study

Y L Zhang et al. Obes Sci Pract. .

Abstract

Aims: The purpose of this study was to examine the effectiveness of beinaglutide on body weight, glycated haemoglobin (HbA1c), blood pressure and lipid profiles in patients with type 2 diabetes mellitus (T2DM) in a real-world setting in China.

Materials and methods: This was a multicentre, observational, retrospective, open-label study conducted in China. Data were collected from T2DM patients who started treatment with beinaglutide between 2017 and 2018.

Results: A total of 314 patients were included in the study. After 3 months of treatment with beinaglutide, there were significant reductions in body weight (-10.05 kg [95% confidence interval -9.29 to -10.80]), HbA1c (-2.87% [-2.62 to -3.11]), 2-h postprandial plasma glucose (-5.46 mmol L-1 [-4.96 to -5.95]) and fasting plasma glucose (-3.04 mmol L-1 [-2.78 to -3.31]) (all p < 0.0001). In addition, 84.96% and 72.18% of the patients achieved weight loss of ≥5% and ≥10%, respectively. Subgroup analyses showed that weight loss was significantly greater in patients with ≥28 kg m-2 of baseline body mass index and 0.60 mg of beinaglutide doses (p = 0.007 and p < 0.0001, respectively). HbA1c reductions were significantly greater in patients with ≥9.0% baseline HbA1c and in those administered 0.40-0.48 mg of beinaglutide doses (all p < 0.0001). Weight loss at 3 months was positively correlated with baseline BMI and the dose of beinaglutide. Positive determinants for HbA1c reduction after 3 months were baseline HbA1c and the dose of beinaglutide.

Conclusions: These observational results confirmed the benefits of beinaglutide in weight loss and glycaemic control and support the use of beinaglutide as an effective treatment for T2DM.

Keywords: Beinaglutide; GLP‐1; T2DM; obesity; weight loss.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that they have no conflicts of interest associated with this study.

Figures

Figure 1
Figure 1
Study flow chart. FAS, full analysis set; HbA1c, glycated haemoglobin.
Figure 2
Figure 2
Temporal trends in body weight between baseline and 3 months. (A) Absolute change in body weight (kg). (B) Relative change in body weight (%). (C) The proportion of patients with weight loss of ≥5%. (D) The proportion of patients with weight loss of ≥10%. The bars show lower limits of 95% CIs. Significant changes from baseline are indicated (*p < 0.01, # p < 0.0001). [Correction added on 10 July 2019, after first online publication: Figure 2 has been replaced in this version.]
Figure 3
Figure 3
Temporal trends of glycaemic parameters between baseline and 3 months. (A) Mean values of HbA1c. (B) Mean values of PPG. (C) Mean values of FPG. (D) Mean change in HbA1c. (E) Mean change in PPG. (F) Mean change in FPG. The bars show lower limits of 95% CIs. Significant changes from baseline are indicated (*p < 0.01, # p < 0.0001). FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; PPG, postprandial glucose.
See this image and copyright information in PMC

References

    1. Zhao X, Guo L, Yuan M, et al. Growing trend of China's contribution to global diabetes research: a systematic literature review. Medicine (Baltimore). 2016; 95: e3517. - PMC - PubMed
    1. Shen X, Vaidya A, Wu S, Gao X. The diabetes epidemic in China: an integrated review of national surveys. Endocr Pract. 2016; 22: 1119–1129. - PMC - PubMed
    1. Bunkenborg M. The uneven seepage of science: diabetes and biosociality in China. Health Place. 2016; 39: 212–218. - PubMed
    1. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013; 310: 948–959. - PubMed
    1. Tao L, Wang L, Yang X, Jiang X, Hua F. Recombinant human glucagon‐like peptide‐1 protects against chronic intermittent hypoxia by improving myocardial energy metabolism and mitochondrial biogenesis. Mol Cell Endocrinol. 2019; 481: 95–103. - PubMed

LinkOut - more resources